# LAI Weekly Newsletter - Week of 2025-12-23

**Generated:** December 23, 2025 | **Items:** 3 signals | **Coverage:** 2 sections

## üéØ TL;DR
‚Ä¢ Teva Pharmaceuticals has submitted a New Drug Application to the U.S. FDA for an undisclosed long-acting injectable (LAI) product, marking a key regulatory milestone.

‚Ä¢ Nanexa and Moderna have entered into a partnership for the development of LAI products, signifying a major deal in the LAI space.

‚Ä¢ No major clinical developments or technology breakthroughs were reported this week.

## üì∞ Introduction
This week's LAI newsletter covers key regulatory updates and a notable partnership deal in the long-acting injectable technology space. Executives can expect insights into recent approvals, filings, and strategic collaborations shaping the landscape.

---

## üìã Regulatory Updates
*2 items ‚Ä¢ Sorted by score*

### üìã Teva Pharmaceuticals has submitted a New Drug Application to the U.S. FDA for Olanzapine Extended-Re
**Source:** press_corporate__medincell ‚Ä¢ **Score:** 10.2 ‚Ä¢ **Date:** Dec 23, 2025

Teva Pharmaceuticals has submitted a New Drug Application to the U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK), a once-monthly treatment for schizophrenia in adults. This is a partnership between Teva and Medincell.

**Key Players:**  ‚Ä¢ **Technology:** 

[**Read more ‚Üí**](https://www.medincell.com/wp-content/uploads/2025/12/MDC_Olanzapine-NDA-filing_09122025_EN_vf-2.pdf)


---

### üìã Teva is preparing to submit a New Drug Application (NDA) to the US FDA for its long-acting injectabl
**Source:** press_corporate__medincell ‚Ä¢ **Score:** 10.2 ‚Ä¢ **Date:** Dec 23, 2025

Teva is preparing to submit a New Drug Application (NDA) to the US FDA for its long-acting injectable (LAI) formulation of olanzapine in Q4 2025. UZEDY, Teva's existing LAI product, continues to show strong growth.

**Key Players:**  ‚Ä¢ **Technology:** 

[**Read more ‚Üí**](https://www.medincell.com/wp-content/uploads/2025/11/PR_MDC_Teva-earnings-Q3_2025_05112025_vf.pdf)


---

## ü§ù Partnerships & Deals
*1 items ‚Ä¢ Sorted by date*

### ü§ù Nanexa and Moderna have entered into a license and option agreement for the development of up to fiv
**Source:** press_corporate__nanexa ‚Ä¢ **Score:** 9.8 ‚Ä¢ **Date:** Dec 23, 2025

Nanexa and Moderna have entered into a license and option agreement for the development of up to five undisclosed compounds using Nanexa's PharmaShell¬Æ technology. Nanexa will receive an upfront payment and is eligible for milestone payments and royalties.

**Key Players:**  ‚Ä¢ **Technology:** 

[**Read more ‚Üí**](https://nanexa.com/mfn_news/nanexa-and-moderna-enter-into-license-and-option-agreement-for-the-development-of-pharmashell-based-products/)


---

## üìä Newsletter Metrics
- **Total Signals:** 3 items processed
- **Sources:** 2 unique sources
- **Key Players:** 
- **Technologies:** 
- **Generated:** 2025-12-23T07:32:23.113721Z
